FDA Approves GLUCAGON — Fresenius Kabi USA, LLC

Fresenius Kabi USA, LLC has received FDA approval for glucagon hydrochloride injection (NDA 201849), enabling the company to further expand its emergency hypoglycemia portfolio. Market analysts expect this expanded formulation to drive incremental sales in the acute care hospital and dispensed pharmacy segments during peak allergy season.